Recruiting
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants - CV027-070
Updated: 15 June, 2022 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Body mass index between 18 and 32 kg/m^2, inclusive, at the Screening Visit - Healthy, as determined by physical examination, vital signs, electrocardiograms (ECGs), and clinical laboratory assessments within the normal range at the screening visit and/or on Day -1 Exclusion Criteria: - Current or recent (within 3 months of study intervention administration) gastrointestinal disease - History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
